首页|加味升降散联合FOLFIRINOX新辅助化疗方案对局部进展期胰腺癌患者的影响

加味升降散联合FOLFIRINOX新辅助化疗方案对局部进展期胰腺癌患者的影响

扫码查看
目的 观察加味升降散联合FOLFIRINOX新辅助化疗方案对局部进展期胰腺癌患者的影响.方法 将84 例局部进展期胰腺癌患者按照随机数字表法分为 2 组,对照组 42 例予基础治疗+FOLFIRINOX新辅助化疗,治疗组42 例在对照组基础上予加味升降散治疗.每2 周为1 个化疗周期,共治疗 6 个化疗周期.比较 2 组治疗前后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原50(CA50)、CA19-9、CA242]、T淋巴细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)、生活质量综合评定量表(GQOL-74)评分,统计 2 组化疗效果、不良反应情况.结果 治疗组客观缓解率23.81%(10/42),对照组客观缓解率7.14%(3/42),治疗组疗效优于对照组(P<0.05).2 组治疗后血清CEA、CA50、CA19-9、CA242 水平均较本组治疗前降低(P<0.05),且治疗组治疗后均低于对照组(P<0.05).2 组治疗后 CD3+、CD4+、CD4+/CD8+水平均较本组治疗前明显升高(P<0.05),且治疗组治疗后均高于对照组(P<0.05);2 组治疗后CD8+水平较本组治疗前明显降低(P<0.05),且治疗组低于对照组(P<0.05).2 组治疗后GQOL-74 各维度评分均较本组治疗前升高(P<0.05),且治疗组治疗后均高于对照组(P<0.05).治疗组不良反应总发生率11.90%,对照组为35.71%,治疗组低于对照组(P<0.05).结论 加味升降散联合FOLFIRINOX新辅助化疗方案治疗局部进展期胰腺癌患者,可有效控制病情进展,增强免疫力,提高生活质量,且不良反应小,预后良好.
Effect of modified Shengjiang Powder combined with neoadjuvant chemotherapy with FOLFIRINOX in patients with lo-cally advanced pancreatic cancer
Objective To observe the effect of modified Shengjiang Powder combined with neoadjuvant chemotherapy with FOLFIRINOX(folinic acid,fluorouracil,irinotecan,and oxaliplatin)in patients with locally advanced pancreatic cancer(LAPC).Methods A total of 84 LAPC patients were randomly assigned into treatment group(n=42)and control group(n=42).All patients were managed by conventional therapy+neoadjuvant chemotherapy with FOLFIRINOX,and those in treatment group were additionally treated with modified Shengjiang Powder.The treatment continued for 6 chemotherapy cycles(1 cycles for 2 weeks),aiming to compare serum tumor markers(carcinoembryonic antigen[CEA],carbohydrate antigen 50[CA50],CA19-9,CA242),T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+),generic quality of life inventory-74(GQOL-74).The chemotherapy effect and adverse reactions were assessed.Results The objective remission rate in the treat-ment group was better than that in the control group(23.81%[10/42]vs7.14%[3/42],P<0.05).After treatment,CEA,CA50,CA19-9,CA242 in the both groups were significantly decreased(P<0.05),which were significantly lower in the treat-ment group than in the control group(P<0.05).Significantly increased CD3+,CD4+,CD4+/CD8+,and decreased CD8+were found in the both groups(all P<0.05),and the treatment group was superior to the control group for CD3+,CD4+,CD4+/CD8+,CD8+(all P<0.05).After treatment,the dimension score of GQOL-74 in the both groups were significantly increased(P<0.05),which was significantly higher in the treatment group than in the control group(P<0.05).The total in-cidence of adverse reactions in the treatment group was significantly lower than that in the control group(11.90%vs 35.71%,P<0.05).Conclusion Modified Shengjiang Powder combined with neoadjuvant chemotherapy with FOLFIRINOX can effec-tively control disease progression,enhance immunity,and improve quality of life in LAPC patients,and it had less adverse reactions and good prognosis.

Pancreatic cancerAntineoplastic combined chemotherapyModified Shengjiang PowderAdjuvantProg-nosis

蒋庭德、魏铮

展开 >

四川省德阳市人民医院中医科,四川 德阳 618000

胰腺癌 抗肿瘤联合化疗方案 加味升降散 辅助 预后

2024

河北中医
河北省医学情报研究所,河北省中医药学会

河北中医

CSTPCD
影响因子:0.951
ISSN:1002-2619
年,卷(期):2024.46(8)